Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics


Rafael Holdings, Inc. Class B (RFL)

Today's Latest Price: $24.61 USD

0.42 (-1.68%)

Updated Jan 20 7:00pm

Add RFL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RFL Stock Summary

  • Rafael Holdings Inc's stock had its IPO on March 27, 2018, making it an older stock than just 8.06% of US equities in our set.
  • For RFL, its debt to operating expenses ratio is greater than that reported by merely 0.52% of US equities we're observing.
  • RFL's price/sales ratio is 83.37; that's higher than the P/S ratio of 96% of US stocks.
  • Stocks that are quantitatively similar to RFL, based on their financial statements, market capitalization, and price volatility, are SHSP, APDN, KERN, DDD, and KVHI.
  • RFL's SEC filings can be seen here. And to visit Rafael Holdings Inc's official web site, go to www.rafaelholdings.com.

RFL Stock Price Chart Interactive Chart >

Price chart for RFL

RFL Price/Volume Stats

Current price $24.61 52-week high $27.75
Prev. close $25.03 52-week low $9.40
Day low $24.29 Volume 32,300
Day high $25.26 Avg. volume 48,392
50-day MA $22.66 Dividend yield N/A
200-day MA $17.17 Market Cap 389.63M

Rafael Holdings, Inc. Class B (RFL) Company Bio


Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation


RFL Latest News Stream


Event/Time News Detail
Loading, please wait...

RFL Latest Social Stream


Loading social stream, please wait...

View Full RFL Social Stream

Latest RFL News From Around the Web

Below are the latest news stories about Rafael Holdings Inc that investors may wish to consider to help them evaluate RFL as an investment opportunity.

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company, will present at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, Jan. 20. “As we kick off 2021, we are excited to present the progress that Rafael Pharmaceuticals has made throughout the past year,” said Sanjeev Luther, President and CEO of Raf...

Yahoo | January 19, 2021

Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference, on Thursday, Jan. 14.Mr. Luther will discuss the status of the Company and milestones it met throughout the year, including receiving two FDA-granted Fast Track designations for its lead compound CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer and the treatment of acute myeloid leukemia (AML). He will also highlight the most recent trial launches, including a Phase 2 clinical trial for patients with clear cell sarcoma of soft tissue.“Rafa...

Yahoo | January 13, 2021

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor Program

The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc., (NYSE: RFL), today announced that it has reached an agreement with Princeton University's Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program and related intellectual property.

Yahoo | December 22, 2020

Rafael Holdings Reports First Quarter Fiscal Year 2021 Results

Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.1 million and a loss per share of $0.09 for the first quarter of its 2021 fiscal year, the three months ended October 31, 2020.

Yahoo | December 15, 2020

UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of acute myeloid leukemia (AML). “Receiving Fast Track designation, especially during a pandemic that has created significant challenges for many trials across the globe, is a testament to the dedicated work of the Rafael team,” said Sanjeev Luther, President and CEO of Rafael. “We would not be here without the support of the FDA, our doctors, our patients, and all who are invested in the hope of finding a successful treatment for this har...

Yahoo | December 15, 2020

Read More 'RFL' Stories Here

RFL Price Returns

1-mo 1.95%
3-mo 45.28%
6-mo 80.16%
1-year 18.83%
3-year N/A
5-year N/A
YTD 5.53%
2020 30.72%
2019 124.97%
2018 N/A
2017 N/A
2016 N/A

Continue Researching RFL

Want to see what other sources are saying about Rafael Holdings Inc's financials and stock price? Try the links below:

Rafael Holdings Inc (RFL) Stock Price | Nasdaq
Rafael Holdings Inc (RFL) Stock Quote, History and News - Yahoo Finance
Rafael Holdings Inc (RFL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8052 seconds.